Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 715 clinical trials
None
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

The rationale for combining lenalidomide with rituximab derives from preclinical observations suggesting that lenalidomide may enhance the ADCC (antigen-dependent cellular cytotoxicity) triggered by monoclonal antibodies such as rituximab. Lenalidomide augments NK cytotoxicity by increasing CD56dimCD3 subset, in addition to inducing IL-2 in T cells. These results provide the cellular and …

monoclonal protein
chronic lymphocytic leukemia
lenalidomide
lymphoma
monoclonal antibodies
  • 18 views
  • 08 Nov, 2020
  • 1 location
None
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

A good proportion of patients with chronic lymphocytic leukemia (CLL) can be managed effectively with palliative chemotherapy. However, there is a group of younger patients with poor risk

bendamustine
anti-cd20 monoclonal antibody
fludarabine
hematologic malignancy
rituximab
  • 12 views
  • 08 Nov, 2020
  • 2 locations
None
Evaluation of Therapeutic Video Games for Pre-school Children With Acute Lymphoblastic Leukemia

The purpose of this study is to evaluate the effectiveness of therapeutic video game.

  • 0 views
  • 10 Sep, 2021
  • 1 location
None
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

20-25% of patients over 15 years with acute lymphoblastic leukemia (ALL) have the Philadelphia chromosome or BCR-ABL rearrangement. Traditionally, intensive chemotherapy followed by

  • 103 views
  • 03 Feb, 2021
  • 112 locations
None
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

This study proposes to provide adequate treatment and is based on current scientific evidence for elderly patients with ALL Bcr / Abl positive. To determine whether low-dose chemotherapy associated with imatinib or dasatinib has acceptable tolerability in elderly patients. To determine whether this association can increase the rate and quality …

  • 1 views
  • 28 Jan, 2021
  • 1 location
None
  • 0 views
  • 17 Feb, 2021
  • 9 locations
None
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)

  • 11 views
  • 21 Oct, 2021
  • 9 locations
None
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: ribociclib everolimus dexamethasone

  • 13 views
  • 06 Aug, 2021
  • 10 locations
None
Single and Multiple Ascending Dose Study With EP395

This is a study to asses the safety and tolerability of single and multiple ascending doses of EP395, administered by oral capsules, in healthy subjects with the aim to determine the safe dose range of EP395 for further clinical development

  • 0 views
  • 06 May, 2021
  • 1 location
None
Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

-cell acute lymphoblastic leukemia. At least 18 subjects will be enrolled. After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and

  • 0 views
  • 11 Sep, 2021
  • 1 location